Search results
Results from the WOW.Com Content Network
Insulin is produced by beta cells in the pancreas. Blood sugar increases shortly after eating as your body breaks down sugars and starches and they’re absorbed by your gastrointestinal tract and ...
IR is insulin resistance and %β is the β-cell function (more precisely, an index for glucose tolerance, i.e. a measure for the ability to counteract the glucose load). Insulin is given in μU/mL. [7] Glucose and insulin are both during fasting. [2] This model correlated well with estimates using the euglycemic clamp method (r = 0.88). [2]
Thus a lowering of disposition index predicts the conversion of insulin resistance to diabetes mellitus type 2. [13] Disposition index, but not insulin resistance, can predict type 2 diabetes in persons with normal blood glucose levels, but who do not have a family history ( genetic predisposition ) to type 2 diabetes.
Beta blockers vary in their lipophilicity (fat solubility) and in turn in their ability to cross the blood–brain barrier and exert effects in the central nervous system. [76] Beta blockers with greater blood–brain barrier permeability can have both neuropsychiatric therapeutic benefits and side effects, as well as adverse cognitive effects ...
The combination of beta blockers and antihypertensive drugs will work on different mechanism to lower blood pressure. [17] For example, the co-administration of beta-1 blocker atenolol and ACE inhibitor lisinopril could produce a 50% larger reduction in blood pressure than using either drug alone. [18]
Betaxolol is a selective beta 1 receptor blocker used in the treatment of hypertension and angina. [1] It is also a adrenergic blocker with no partial agonist action and minimal membrane stabilizing activity. [2]
Moxonidine is a new-generation alpha-2/imidazoline receptor agonist antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. [5] [6] It may have a role when thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or have failed to control blood pressure.
Figure 1: The chemical structure of dichloroisoprenaline or dichloroisoproterenol (), abbreviated DCI — the first β-blocker to be developed. β adrenergic receptor antagonists (also called beta-blockers or β-blockers) were initially developed in the 1960s, for the treatment of angina pectoris but are now also used for hypertension, congestive heart failure and certain arrhythmias. [1]